Search results for "antibody"

showing 10 items of 1896 documents

Immune Response to Gelatin- and Collagen-Impregnated Aortic Dacron Grafts

1996

Dacron grafts are very common in vascular surgery. Primarily sealed grafts have been available for ten years. These improve handling and reduce intraoperative blood loss. Despite a widespread use all over the world, it has as yet not been clarified whether coating (sealing) substances might cause an immune response, especially in situations of fever or other unexplained events in the postoperative course after graft implantation. In this study, 37 patients with a gelatin-impregnated (Unigraft) and 33 with a collagen-impregnated (Hemashield) graft for aortic or aortoiliac replacement were compared. Serum samples were investigated for collagen antibodies at operation, one week and three mont…

medicine.medical_specialtyAortabiologybusiness.industrymedicine.medical_treatmentPerioperative030204 cardiovascular system & hematologyVascular surgeryRevascularizationProsthesisSurgery03 medical and health sciences0302 clinical medicinemedicine.arteryCirculatory systemmedicinebiology.protein030212 general & internal medicineAntibodyCardiology and Cardiovascular MedicineComplicationbusinessVascular Surgery
researchProduct

The inhibitors - a challenge for the management of patients with hereditary haemophilia A.

2018

Abstract Introduction. Our research strategy was aimed at evaluating the possible implication of the type of factor VIII product administered as substitution treatment to haemophilia A patients in the occurrence of inhibitors and their consequences on the management. Methods. Scientific articles from July 2015 to July 2017 were searched using the PubMed and PubMed Central databases. The used search terms included “haemophilia A”, “inhibitors”, “plasma-derived factor VIII” and “recombinant factor VIII”. Results. The risk factors for inhibitors occurrence may be patients-related (genetic and nongenetic) and treatment-related. The possibility of a correlation between the increased purity of fa…

medicine.medical_specialtyBispecific antibodyHaemophilia A030204 cardiovascular system & hematologyBioinformaticsHemophilia AFactor VIII productRecombinant factor viii03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesinhibitorsmedicineHumansInternal medicineFactor VIIIbusiness.industryhaemophilia amedicine.diseaseplasma-derived factor viiiRC31-1245Recombinant Proteinsneutralizing alloantibodiesSearch termsCoagulationrecombinant factor viiibusiness030215 immunologyRomanian journal of internal medicine = Revue roumaine de medecine interne
researchProduct

Transient focal cerebral ischemia significantly alters not only EAATs but also VGLUTs expression in rats: relevance of changes in reactive astroglia

2010

The involvement of plasma membrane glutamate transporters (EAATs - excitatory aminoacid transporters) in the pathophysiology of ischemia has been widely studied, but little is known about the role of vesicular glutamate transporters (VGLUTs) in the ischemic process. We analyzed the expression of VGLUT1-3 in the cortex and caudate-putamen of rats subjected to transient middle cerebral artery occlusion. Western blot and immunohistochemistry revealed an increase of VGLUT1 signal in cortex and caudate-putamen until 3 days of reperfusion followed by a reduction 7 days after the ischemic insult. By contrast, VGLUT2 and 3 were drastically reduced. Confocal microscopy revealed an increase in VGLUT2…

medicine.medical_specialtyBlotting WesternIschemiaFluorescent Antibody TechniqueGlutamic AcidBiologyBiochemistryBrain ischemiaGlutamate Plasma Membrane Transport ProteinsCellular and Molecular NeuroscienceCell MovementInternal medicineNeuroblast migrationCortex (anatomy)Vesicular Glutamate Transport ProteinsmedicineAnimalsCerebral CortexMicroscopy ConfocalNeuronal PlasticityCell DeathNeurogenesisPutamenGlutamate receptorInfarction Middle Cerebral Arterymedicine.diseaseImmunohistochemistryRatsEndocrinologymedicine.anatomical_structureIschemic Attack TransientAstrocytesReperfusion InjuryExcitatory postsynaptic potentialCaudate NucleusNeurogliaReperfusion injuryNeuroscienceJournal of Neurochemistry
researchProduct

Coexpression of vasoactive intestinal peptide, calcitonin gene-related peptide and substance P immunoreactivity in parasympathetic neurons of the rhe…

1995

Abstract By the use of light microscopic immunohistochemistry, the present study investigates whether substance P (SP) and calcitonin generelated peptide (CGRP), which are well documented neurotransmitter candidates in primary sensory fibers, are also expressed in parasympathetic neurons of the rhesus monkey lung. A combination of double fluorescence immunohistochemistry and staining of adjacent sections revealed triple coexistence of SP, CGRP and the cholinergic co-transmitter vasoactive intestinal peptide (VIP) in a large number of neuronal cell bodies in intrinsic peribronchial ganglia. In addition, there was co-localization of SP and CGRP in choline acetyltransferase (ChAT)-positive neu…

medicine.medical_specialtyCalcitonin Gene-Related PeptideVasoactive intestinal peptideNeuropeptideSubstance PSubstance PCalcitonin gene-related peptideBiologyCholine O-Acetyltransferasechemistry.chemical_compoundParasympathetic Nervous SystemInternal medicinemedicineAnimalsLungNeuronsGeneral NeuroscienceImmunohistochemistryMacaca mulattaCholine acetyltransferaseEndocrinologynervous systemchemistryFluorescent Antibody Technique DirectCalcitoninCholinergicAcetylcholineVasoactive Intestinal Peptidemedicine.drug
researchProduct

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission in…

2019

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its con…

medicine.medical_specialtyCardiologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMaintenance Chemotherapy03 medical and health sciencesRemission induction0302 clinical medicineMaintenance therapymedicineHumans030212 general & internal medicineMedical prescriptionIntensive care medicineSocieties Medical030203 arthritis & rheumatologybusiness.industryRemission InductionGranulomatosis with PolyangiitisGeneral Medicinemedicine.diseaseBiological TherapyPractice Guidelines as TopicRituximabFranceGranulomatosis with polyangiitisbusinessMicroscopic polyangiitisVasculitisMepolizumabImmunosuppressive Agentsmedicine.drugLa Presse Médicale
researchProduct

BMP-2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials.

2012

Objectives Combination of scaffolds and growth factors is a promising option for several clinical problems in bone biomaterials. Simplified growth factor loading by adsorption from aqueous solution is one important option for this technology. We evaluated the adsorption followed by PBS rinsing, release and biological effect of transient loading with basic fibroblast growth factor (bFGF) and bone morphogenic protein 2 (BMP-2) on fresh frozen bone, processed bone matrix, collagen, and a ceramic material with immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and qRT-PCR. Materials and methods The study consisted of three in vitro experiments (immunofluorescence, ELISA, and qRT-PCR…

medicine.medical_specialtyCeramicsTime Factorsmedicine.medical_treatmentBasic fibroblast growth factorOsteocalcinCell Culture TechniquesBone MatrixBone Morphogenetic Protein 2Fluorescent Antibody TechniqueBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitEnzyme-Linked Immunosorbent AssayBone healingMatrix (biology)Bone morphogenetic proteinBone morphogenetic protein 2Bone and Boneschemistry.chemical_compoundmedicineAnimalsHumansCells CulturedOsteoblastsbiologyTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionGrowth factorOsteoblastAlkaline PhosphataseSurgerymedicine.anatomical_structureDurapatitechemistryDelayed-Action PreparationsOsteocalcinbiology.proteinBiophysicsNanoparticlesFibroblast Growth Factor 2AdsorptionCollagenOral SurgeryBiomarkersClinical oral implants research
researchProduct

Chronic ulcerative stomatitis : a systematic review of the clinical and microscopic features

2019

Made available in DSpace on 2020-12-12T02:29:00Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-11-01 Background: the purpose of this study was to perform a systematic review regarding clinical and histopathological characteristics, immunopathological findings, and treatment for chronic ulcerative stomatitis (CUS). Material and Methods: articles in English, published from January 1962 up to November 2017, assessing clinical and immunological features, treatment, and follow-up of patientes with CUS, were retrieved from three databases (PubMed, Cochrane Library and SCOPUS). A manual literature search was also conducted. A total of 12 studies met inclusion criteria, therefore, were anal…

medicine.medical_specialtyChronic ulcerative stomatitisImmunofluorescenceMEDLINEReviewCochrane Library03 medical and health sciencesGingivitis0302 clinical medicineChronic ulcerative stomatitismedicineHumansGeneral DentistryDirect fluorescent antibodyLichenoid lesionsOral Medicine and Pathologybusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyGingivitis Necrotizing Ulcerativestomatognathic diseasesChronic diseaseOtorhinolaryngologyChronic DiseaseUNESCO::CIENCIAS MÉDICASSurgeryOral lichen planusImmune-mediated diseasesmedicine.symptomLichen planusbusinessLichen Planus Oral
researchProduct

Response of patients with chronic Hepatitis B in one year of treatment with Major Autohemotherapy.

2018

The Hepatitis B (HVB) is one of the most common infectious diseases in the world, it’s wide geographical distribution is a health problem, especially on the African continent, with prevalence rate of 6.1% in the adult population. Current treatment requires prolonged therapy (most cases for the rest of life) with the aim of stopping viral replication, maintaining immunological stability, preventing progression of liver disease and the most feared complications such as cirrhosis and hepatic cancer
 There are multiple references that point to ozone therapy as an alternative in the treatment of Hepatitis B, because of the known and demonstrated antimicrobial and immunomodulatory properties…

medicine.medical_specialtyCirrhosisbiologybusiness.industryHepatitis B:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOzone therapyGastroenterologyAutohemotherapyLiver diseaseAntigenInternal medicineUNESCO::CIENCIAS MÉDICASmedicinebiology.proteinAntibodybusinessViral loadJournal of Ozone Therapy
researchProduct

Acquired haemophilia in cancer: A systematic and critical literature review

2017

Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…

medicine.medical_specialtyContext (language use)Antineoplastic AgentsFactor VIIa030204 cardiovascular system & hematologyMalignancyHemophilia AGastroenterology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsAcquired haemophiliamedicineHumanscancerhaematological malignancyGenetics (clinical)Blood Coagulation Factor Inhibitorstreatmentbusiness.industryIncidence (epidemiology)AutoantibodyCancerHematologyGeneral Medicinemedicine.diseasebleedingBlood Coagulation FactorsRecombinant ProteinsSurgeryinhibitordiagnosiSystematic reviewTreatment Outcome030220 oncology & carcinogenesisHematologic Neoplasmsacquired haemophilabusinessHaematological malignancy
researchProduct

Optimization of hepatitis C virus screening strategies by birth cohort in Italy

2020

Abstract Background and Aims Cost‐effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost‐effective in Italy. Methods A model was developed to quantify screening and healthcare costs associated with HCV. The model‐estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost‐effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies. Results A graduated birth cohort screening strat…

medicine.medical_specialtyCost effectivenessCost-Benefit AnalysisHepatitis C virusSettore SECS-P/06cost-effectiveneHepacivirusmedicine.disease_causeAntiviral AgentsWorld healthNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMass Screeningcost-effectivenessAntibody screensHepatologyUnder-fivebusiness.industryscreeningHealth services researchhealthcost‐effectivenessHepatitis C ChronicHepatologyHepatitis CItaly030220 oncology & carcinogenesisSettore MED/42HCVOriginal Articleepidemiology030211 gastroenterology & hepatologyLiver Disease and Public HealthQuality-Adjusted Life YearsBirth cohortbusinessWHO targetscost-effectiveness HCV screening WHO targetsDemography
researchProduct